Overexpression of the c‐erbB‐2 protein in human breast tumor cell lines

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Journal of Cellular Biochemistry

• Publication date

  1989-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/jcb.240390208PMID 2565909
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.

  1988cited by this paper
• Activation of the receptor kinase domain of the trk oncogene by recombination with two different cellular sequences.

  1988cited by this paper
• The transformation of primary and established mouse mammary epithelial cells by p21-ras is concentration dependent.

  1988cited by this paper
• Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms.

  1987cited by this paper
• The molecular genetics of cancer.

  1987cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene

  1987cited by this paper
• Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.

  1987cited by this paper
• Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

  1987cited by this paper
• erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

  1987cited by this paper
• Characterization of the promoter region of the human c-erbB-2 protooncogene.

  1987cited by this paper
• Expression of the c‐erbB‐2 protein in normal and transformed cells

  1987cited by this paper
• Characterization of the promoter region of the human c-erb B-2 proto-oncogene

  1987cited by this paper
• Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation

  1987cited by this paper
• Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor

  1986cited by this paper
• Oncogene amplification in tumor cells.

  1986cited by this paper
• A v-erbB-related protooncogene, c-erb-B-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma

  1985cited by this paper
• A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.

  1985cited by this paper
• Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

  1985cited by this paper
• Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.

  1985cited by this paper
• Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

  1985cited by this paper
• The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

  1984cited by this paper
• Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

  1984cited by this paper
• Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

  1984cited by this paper
• Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

  1981cited by this paper
• Epidermal growth factor.

  1979cited by this paper
• Detection of specific sequences among DNA fragments separated by gel electrophoresis.

  1975cited by this paper
• Ribonucleic acid isolated by cesium chloride centrifugation.

  1974cited by this paper

• Automated Classification of Breast Cancer Across the Spectrum of ERBB2 Expression Focusing on Heterogeneous Tumors With Low Human Epidermal Growth Factor Receptor 2 Expression

  2023cites this paper
• Bifunctional Recombinant Protein Agent Based on Pseudomonas Exotoxin A Fragment for Targeted Therapy of HER2-Positive Tumors

  2018cites this paper
• Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response

  2018cites this paper
• Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro

  2017cites this paper
• Complexes of magnetic nanoparticles and scFv antibodies for targeting and visualizing cancer cells

  2015cites this paper
• Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?

  2014cites this paper
• Feasibility study of the optical imaging of a breast cancer lesion labeled with upconversion nanoparticle biocomplexes

  2013cites this paper
• Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.

  2013cites this paper
• Inhibiting Tumor Protein D52 function for anti-cancer therapy application

  2013cites this paper
• Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation

  2012cites this paper
• HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ

  2012cites this paper
• ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective

  2012cites this paper
• Fluorescent IgG fusion proteins made in E. coli

  2012cites this paper
• Secretion of Novel SEL1L Endogenous Variants Is Promoted by ER Stress/UPR via Endosomes and Shed Vesicles in Human Cancer Cells

  2011cites this paper
• Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins

  2010cites this paper
• Copine-III interacts with ErbB2 and promotes tumor cell migration

  2010cites this paper
• Phosphoinositide 3-kinase targeting by the β galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death

  2009cites this paper
• Current perspective - trastuzumab.

  2009cites this paper
• Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival

  2008cites this paper
• Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.

  2008cites this paper
• Antibody internalization studied using a novel IgG binding toxin fusion.

  2007cites this paper
• An EGR2/CITED1 Transcription Factor Complex and the 14-3-3σ Tumor Suppressor Are Involved in Regulating ErbB2 Expression in a Transgenic-Mouse Model of Human Breast Cancer

  2007cites this paper
• Dissecting the molecular mechanisms of cancer through bioinformatics‐based experimental approaches

  2007cites this paper
• An EGR2/CITED1 Transcription Factor Complex and the 14-3-3 (cid:2) Tumor Suppressor Are Involved in Regulating ErbB2 Expression in a Transgenic-Mouse Model of Human Breast Cancer (cid:1)

  2007cites this paper
• Herceptin® – from laboratory to cure in breast cancer?

  2007cites this paper
• Herceptin – from bedside to bench to clinic?

  2007cites this paper
• Analysis of CerbB2 protein content of human glioma cells and tumor tissue

  2005cites this paper
• The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade

  2005cites this paper
• Contrôle de la mort cellulaire par la voie des MAPK1/3 (ERK2/1)

  2005cites this paper
• Amplification and differential expression of members of theerbB-gene family in human glioblastoma

  2005cites this paper
• Evaluation der HER-2/neu-Genamplifikation an Tumorabklatschpräparaten von Mammakarzinomen mittels FISH und deren Wertigkeit im Vergleich zur immunhistochemischen membranassoziierten Proteinüberexpression

  2005cites this paper
• Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

  2004cites this paper
• Expression of the c-erbB-2-encoded oncoprotein and progesterone receptor in human meningiomas

  2004cites this paper
• Selective inhibition of cell proliferation and DNA synthesis by the polysulphated carbohydrate ι-carrageenan

  2004cites this paper
• Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification.

  2003cites this paper
• HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue.

  2003cites this paper
• The ErbB2 receptor and breast carcinoma cell migration : memo is a novel mediator of cell motility

  2003cites this paper
• Replacement of N‐terminal portions of TGF‐α with corresponding heregulin sequences affects ligand‐induced receptor signaling and intoxication of tumor cells by chimeric growth‐factor toxins

  2002cites this paper
• Advances in Brief A New Human Antitumor Immunoreagent Specific for ErbB 21

  2002cites this paper
• A new human antitumor immunoreagent specific for ErbB2.

  2002cites this paper
• Anti‐human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer

  2002cites this paper
• Regulation of MUC1 Expression in Human Mammary Cell Lines by the c-ErbB2 and Ras Signaling Pathways

  2001cites this paper
• Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis.

  2001cites this paper
• Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells

  2001cites this paper
• An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway.

  2001cites this paper
• Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe.

  2001cites this paper
• HER2/neu Gene Amplification Quantified by PCR and Melting Peak Analysis Using a Single Base Alteration Competitor as an Internal Standard

  2001cites this paper
• Relative Quantification of the HER2/neu Oncogene Using SYBR Green I

  2001cites this paper
• Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.

  2001cites this paper
• Weekly T rastuzumab a nd P aclitaxel T herapy f or M etastatic Breast C ancer W ith A nalysis o f E fficacy b y HER2 Immunophenotype a nd G ene A mplification

  2001cites this paper
• Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

  2001cites this paper
• HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer.

  2001cites this paper
• HER2 TESTING RECOMMENDATIONS IN AUSTRALIA

  2001cites this paper
• Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.

  2001cites this paper
• Targeting HER2 in other tumor types.

  2001cites this paper
• Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo

  2000cites this paper
• HER2/neu: A Target for Breast Cancer Therapy

  2000cites this paper
• Assessment of HER2 status in breast cancer: why, when and how?

  2000cites this paper
• Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines.

  2000cites this paper
• The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors.

  2000cites this paper
• Positive and negative regulation of endogenous genes by designed transcription factors.

  2000cites this paper
• c-Src, receptor tyrosine kinases, and human cancer.

  1999cites this paper
• Toward selection of internalizing antibodies from phage libraries.

  1999cites this paper
• NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways

  1999cites this paper
• ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases*

  1999cites this paper
• Prognostic value of immunohistochemical expression of the c‐erbB‐2 oncoprotein in metastasic prostate cancer

  1999cites this paper
• Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2.

  1999cites this paper
• Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications.

  1999cites this paper
• Molecular Chemotherapy for Breast Cancer

  1999cites this paper
• Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)–carbonyl complex

  1999cites this paper
• Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells.

  1998cites this paper
• Retinoids control the expression of c-erbB receptors in breast cancer cells.

  1998cites this paper
• ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner

  1998cites this paper
• Soluble HER‐2/neu neutralizes biologic effects of anti‐HER‐2/neu antibody on breast cancer cells in vitro

  1997cites this paper
• Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification.

  1997cites this paper
• Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cells.

  1997cites this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cites this paper
• Targeted tumor cytotoxicity mediated by intracellular single-chain anti-oncogene antibodies.

  1997cites this paper
• Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.

  1997cites this paper
• Molecular and cellular biology of prostate cancer

  1997cites this paper
• An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2

  1997cites this paper
• C-erbB-2: expression in patients with breast carcinoma in comparison to patients with benign breast diseases.

  1996cites this paper
• Inhibition of erbB-2-Positive Breast Cancer Cell Growth by erbB-2 Antisense Oligonucleotides

  1996cites this paper
• Epidermal Growth Factor-related Peptides Activate Distinct Subsets of ErbB Receptors and Differ in Their Biological Activities (*)

  1996cites this paper
• Gene amplification for c-erbB-2, c-myc, epidermal growth factor receptor, int-2, and N-myc measured by quantitative PCR with a multiple competitor template.

  1995cites this paper
• Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling

  1995influential citation
• NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells.

  1995cites this paper
• EGF receptor and p185erbB‐2‐specific single‐chain antibody toxins differ in their cell‐killing activity on tumor cells expressing both receptor proteins

  1995cites this paper
• Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2

  1995cites this paper
• ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin‐embedded breast carcinoma tissues

  1995cites this paper
• 4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.

  1995cites this paper
• Targeted inhibition of tumor‐cell growth by recombinant heregulin‐toxin fusion proteins

  1995cites this paper
• The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma.

  1995cites this paper
• Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells.

  1994cites this paper
• ErbB‐2 expression in estrogen‐receptor‐positive breast‐tumor cells is regulated by growth‐modulatory reagents

  1994cites this paper
• Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms.

  1994cites this paper
• The pathology of low-grade adenosquamous carcinoma of the breast. An immunohistochemical study.

  1994cites this paper
• Intracellular expression of single chain antibodies reverts ErbB-2 transformation.

  1994cites this paper
• 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.

  1994cites this paper
• Measuring c-erbB-2 oncogene amplification in fresh and paraffin-embedded tumors by competitive polymerase chain reaction.

  1994influential citation